PMI CEO Speaking at Barclays

Philip Morris International (PM) has successfully shifted focus from cigarettes to higher-margin smoke-free products, driving strong Q2 results. Revenue hit $11B, up 10.4%, with adjusted EPS at $2.20, up 15.2%. Smoke-free products now make up 42% of revenue, with management targeting over two-thirds by 2030. The stock has returned 137% over five years, but is not considered cheap.

Altria (MO) raised its quarterly dividend by 4.7% to $1.11/share, yielding ~6.4% at $68.37. The company has a strong free cash flow history but faces revenue decline and high debt. It guided for mid-single-digit dividend growth through 2028 and has a new contract manufacturing deal with Philip Morris International.

The FDA authorized 11 new ZYN nicotine pouch products by Philip Morris International, citing lower harmful constituents. The agency considered risks and benefits, aiming to provide adult smokers with less harmful alternatives. The decision aligns with a shift towards tobacco harm reduction, with studies showing nicotine products' role in smoking cessation.

Altria Group (MO) stock rose after announcing a contract manufacturing deal with Philip Morris International (PM) affiliates to improve efficiency in tobacco operations. Initial shipments are expected in early 2027. The agreement supports Altria's 2028 goals but is not expected to impact 2026 financial results. MO traded at $67.84, with mixed technical indicators and a Hold consensus rating. PM shares also rose. According to Benzinga Pro, MO was up 3.87% and PM was up 2.60% at the time of public

Philip Morris International (PMI) and Altria have signed contract manufacturing deals to boost exports and imports. Altria will benefit from a tax rebate, while PMI maintains no U.S. sales plans. First shipments are expected in 2027, with no impact on 2026 performance. Altria expects a profit boost in late 2026 from similar partnerships.

Philip Morris International and Altria have signed contract manufacturing deals to boost cigarette imports and exports. Altria will benefit from a U.S. tax rebate, while PMI maintains no U.S. sales plans. First shipments are expected in 2027, with no 2026 performance impact. Altria expects a 2026 profit boost from similar partnerships.